Previously untreated HL: early PET response-adapted treatment yields impressive 5-y PFS

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Significantly improved 5-y PFS was seen in patients with Hodgkin's lymphoma (HL) who switched to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) + involved-node radiotherapy (INRT) after positive positron emission tomograp...